Phospho-Bcr (Tyr177) Antibody

• 产品编号：CST-3901S      品牌：CST       原厂货号：3901S
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

Phospho-Bcr (Tyr177)兔多抗能检测酪氨酸（177位点）磷酸化的内源性Bcr、Bcr-Abl蛋白水平。该多克隆抗体通过使用与人源Bcr蛋白酪氨酸（177位点）周围残基相一致的磷酸化的合成肽段免疫动物而获得。该抗体经蛋白A和肽亲和层析纯化。Bcr蛋白基因最早在嵌合的 Bcr-Abl致癌基因中发现(1)，Bcr蛋白胺端区域包含一个寡聚化反应区域——丝氨酸/苏氨酸激酶区域，以及能结合SH2的区域。该蛋白质中心区域有一个PH结构域和一个与鸟苷酸交换因子序列相近的区域，是Rho家族的GTP结合蛋白。C端区域可能涉及到一个对小GTP结合蛋白Rac 的GTP酶活化作用(2,3)。原株Bcr in细胞的作用机制尚不清楚。PDGF受体可能将Bcr蛋白当作下游信号调节子来使用(4)。研究表明Bcr-Abl的融合导致结构性活化酪氨酸激酶的产生，该激酶会引起白血病（CML）(5). Bcr-Abl融合蛋白中Bcr蛋白酪氨酸（177位点）被磷酸化，该磷酸化作用对转变Bcr-Abl蛋白的活性十分重要(6)。磷酸化的酪氨酸（177位点）为Gab2 、GRB2提供了一个“停泊位点”(7,8)。

1. Groffen, J. et al. (1984) Cell 36, 93-99.
2. Maru, Y. et al. (1991) Cell 67, 459-468.
3. Che, W. et al. (2001) Circulation 104, 1399-1406.
4. Abe, J. I. et al. (2001) Ann. N.Y. Acad. Sci. 947, 341-343.
5. Voncken, J. W. et al. (1995) Cell 80, 719-728.
6. He, Y. et al. (2002) Blood 99, 2957-2968.
7. Sattler, M. et al. (2002) Cancer Cell 1, 479-492.
8. Warmuth, M. et al. (1995) J. Biol. Chem. 272, 33260-33270.

原厂资料：

Specificity / Sensitivity

Phospho-Bcr (Tyr177) Antibody detects endogenous levels of Bcr and Bcr-Abl only when phosphorylated at tyrosine 177.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr177 of human Bcr. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The Bcr gene was orginally identified by its presence in the chimeric Bcr-Abl oncogene (1). The amino-terminal region of Bcr contains an oligomerization domain, a serine/threonine kinase domain and a region that binds SH2 domains. The middle of the protein has a PH domain and a region of sequence similarity to the guanine nucleotide exchange factors for the Rho family of GTP binding proteins. The carboxy-terminal region may be involved in a GTPase activating function for the small GTP-binding protein Rac (2,3). The function of wild type Bcr in cells remains unclear. PDGF receptor may use Bcr as a downstream signaling mediator (4). The Bcr-Abl fusion results in production of a constitutively active tyrosine kinase, which causes chronic myelogenous leukemia (CML) (5). Tyr177 of Bcr is phosphorylated in the Bcr-Abl fusion protein, which plays an important role in transforming the activity of Bcr-Abl (6). Phosphorylated Tyr177 of Bcr provides a docking site for Gab2 and GRB2 (7,8).

1. Groffen, J. et al. (1984) Cell 36, 93-99.
2. Maru, Y. et al. (1991) Cell 67, 459-468.
3. Che, W. et al. (2001) Circulation 104, 1399-1406.
4. Abe, J. I. et al. (2001) Ann. N.Y. Acad. Sci. 947, 341-343.
5. Voncken, J. W. et al. (1995) Cell 80, 719-728.
6. He, Y. et al. (2002) Blood 99, 2957-2968.
7. Sattler, M. et al. (2002) Cancer Cell 1, 479-492.
8. Warmuth, M. et al. (1995) J. Biol. Chem. 272, 33260-33270.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody.